Results from the VeriStrat analysis of serum or plasma samples taken from a Phase 2 study evaluating erlotinib (Tarceva; Genentech), gemcitabine (Gemzar; Lily), and erlotinib plus gemcitabine in elderly advanced NSCLC patients were presented at the Chicago Multidisciplinary Symposium in Thoracic Oncology.
VeriStrat testing was performed on pretreatment serum or plasma samples from 105 study patients with classifications of 63 as VeriStrat Good (60%) and 35 as VeriStrat Poor (33%). Results showed in the gemcitabine treated arm, there was no significant difference between patients classified as VeriStrat Good and VeriStrat Poor for both progression free survival (PFS) and overall survival (OS). However, in the erlotinib treated arm, patients classified as VeriStrat Good had a statistically significant improvement in PFS (P=0.002) and OS (P=0.014) compared to patients classified as VeriStrat Poor. Patients classified as VeriStrat Good also had better PFS (P=0.027) and a strong trend toward better OS outcomes (P=0.051) in the erlotinib plus gemcitabine arm compared to patients classified as VeriStrat Poor.
Researchers concluded in multivariate analysis that the VeriStrat test was predictive of both PFS and OS outcomes between erlotinib and gemcitabine arms (P<0.001, P=0.017, respectively) and that further studies utilizing VeriStrat to select more beneficial treatment regimens for lung cancer patients are warranted.
VeriStrat is a blood-based test for patients with cancer that provides results on the patient’s proteomic profile. The test helps physicians make more informed treatment decisions by identifying patients who are likely to have good or poor outcomes after treatment with specific cancer therapies. Samples are processed in Biodesix’ CLIA-certified laboratory and results are reported in <72 hours. VeriStrat has been validated in clinical studies with >3000 cancer patients.
For more information visit www.biodesix.com.
This article originally appeared on MPR